重组人干扰素α-2b局部注射联合口服泛昔洛韦治疗频发性生殖器疱疹疗效研究

目的 观察局部注射重组人干扰素α-2b注射液联合口服泛昔洛韦治疗频发性生殖器疱疹的临床疗效及复发率.方法 86例频发性生殖器疱疹患者,其中男性63例,女性23例;年龄19～54岁,平均年龄46.5岁.随机分为2组,联合组44例,对照组42例.联合组给予口服泛昔洛韦片0.25g,3次/天,连续服用5d,同时在皮损基底部呈...     

更昔洛韦治疗疱疹性咽峡炎80例临床分析

目的 观察更昔洛韦治疗疱疹性咽峡炎的疗效。方法 将同期疱疹性咽峡炎的患儿156例随机分为治疗组（更昔洛韦）80例及对照组（病毒唑）76例进行比较。结果 治疗组再退热时间、疱疹消失时间均少于对照组（P〈0．01）。结论 更昔洛韦治疗疱疹性咽峡炎疗效显著，可以广泛应用。     

匹多莫德片治疗复发性生殖器疱疹的疗效分析

目的 探讨匹多莫德片治疗复发性生殖器疱疹的疗效分析.方法 将复发性生殖器疱疹患者122例按照1∶1的比例随机分成对照组和观察组,每组各61例.对照组应用盐酸伐昔洛韦片治疗.观察组在对照组治疗的基础上联合匹多莫德片治疗.结果 观察组总有效率为93.4％,对照组的总有效率为80.32％,其差异有统计学意义(P＜0.05).观察组患者的症状消失、结痂、止疱、皮损愈合时间短于对照组患者的症状消失、结痂、止疱、皮损愈合时间,其差异显著(P＜0.01).治疗后,观察组患者的CD3+、CD4+、CD4 +/CD8+水平高于对照组患者的CD3+、CD4+、CD4 +/CD8+,且观察组CD8+水平则低于对照组患者的CD8+水平,差异显著(P＜0.01).随访6个月和12个月显示,观察组复发率为24.59％、44.26％少于对照组的42.62％、70.49％,差异有统计学意义(P＜0.05).结论 匹多莫德片治疗复发性生殖器疱疹疗效确切,能够有效调节患者的细胞免疫,提高患者的免疫抵抗力,降低患者的复发率.     

苦参碱注射液对婴儿巨细胞病毒性肝炎患者肿瘤坏死因子-α（TNF-α）的影响

目的苦参碱注射液对婴儿巨细胞病毒性肝炎患者肿瘤坏死因子-α（TNF-α）的影响。方法将42例婴儿巨细胞病毒（CMV）肝炎患儿随机分为苦参碱治疗组（n=22）与更昔洛韦对照组（n=20）。两组均予以常规保肝降酶治疗为基础。苦参碱治疗组用苦参碱注射液20-25mg/d静脉滴注,每日1次,连用14天;间隔7-10天后20-25mg/kg.d静脉滴注,每日1次,连用5天,共2-3个疗程。更昔洛韦对照组用更昔洛韦5mg/kg.d静脉滴注,每日2次,连用14天;间隔7-10天后5mg/kg.d静脉滴注,每日1次,连用5天,共2-3个疗程。观察两组TNF-α水平变化。结果治疗前、后苦参碱注射液对血TNF-α、TBIL、ALT的变化。（P〈0.01）。结论苦参碱注射液治疗婴儿巨细胞病毒性肝炎疗效确切,可能与抑制TNF-α释放有关。     

丙种球蛋白治疗新生儿巨细胞病毒肺炎的临床疗效分析

目的探讨丙种球蛋白治疗新生儿巨细胞病毒感染性肺炎的疗效和安全性。方法回顾于2000年7月至2006年3月入院的24例新生儿巨细胞病毒感染性肺炎患儿,随机分为两组进行对照研究,入选患儿常规抗生素治疗,明确病原后予对因治疗,对照组应用更昔洛韦,每次5mg/kg,每12h1次,疗程14d;治疗组用静脉用丙种球蛋白每日400mg/kg,疗程10d。观察项目:①临床指标:住院天数、肺部体征开始消退时间。②实验室指标:血常规、肝功能、HCMV-DNA量的变化。③随访观察:出院后每3个月随访一次,包括临床表现、体征和FQ-PCR测定HCMV-DNA拷贝数。结果静脉用丙种球蛋白治疗组有效率81.8%,治疗组有效率53.8%,两组疗效相近,差异无统计学意义(χ2=2.329,P>0.05),治疗组平均住院日为(23±5.6)d,对照组为(28.6±7)d,差异有统计学意义(t=-2.164,P<0.05)。肺部体征开始消退天数分别为(7.45±1.37)d和(9.58±2.61)d,存在统计学差异(t=-2.415,P<0.05)。对照组有2例因WBC<0.5×109/L,plt<25×109/L,而终止治疗,1例治疗过程中死于呼吸衰竭。结论丙种球蛋白治疗新生儿巨细胞病毒感染性肺炎疗效与更昔洛韦相近,相对于更昔洛韦,在治疗新生儿巨细胞病毒感染性肺炎,特别是合并多种病原体混合感染,静脉用丙种球蛋白具有较好的疗效和安全性。     

更昔洛韦联合复方倍他米松治疗头面部带状疱疹疗效观察

本研究应用更昔洛韦联合复方倍他米松治疗头面部带状疱疹取得较好疗效，现报道如下。     

复方甘草酸苷联合左西替利嗪及酮替芬治疗慢性荨麻疹的临床效果

目的:探讨复方甘草酸苷联合左西替利嗪及酮替芬治疗慢性荨麻疹的疗效和可行性。方法:选取2015年6月至2016年6月我院收治的80例慢性荨麻疹患者,随机分为对照组(38例)和治疗组(42例)。对照组以左西替利嗪和酮替芬治疗。在对照组治疗基础上,治疗组加服复方甘草酸苷胶囊75mg tid。均连用4周后,比较两组的有效率。结果:治疗组和对照组有效率分别为85.71%和57.89%。两组比较差异有统计学意义(P0.01)。结论:复方甘草酸苷联合左西替利嗪及酮替芬治疗慢性荨麻疹的疗效满意,值得临床选择应用。     

地氯雷他定联合复方甘草酸苷胶囊治疗慢性荨麻疹的疗效观察

目的观察地氯雷他定联合复方甘草酸苷治疗慢性荨麻疹的疗效。方法将84例荨麻疹患者随机分为两组,治疗组46例用地氯雷他定及复方甘草酸苷片治疗,对照组38例用地氯雷他定治疗,两组患者分别治疗4w后观察临床疗效。结果治疗组总有效率93.5%,对照组总有效率65.8%,两组比较有显著性差异(<0.01);两组用药期间均无明显不良反应。结论地氯雷他定联合复方甘草酸苷治疗慢性荨麻疹疗效显著,不良反应少,值得临床推广。     

更昔洛韦与干扰素联合治疗儿童病毒性脑膜炎临床疗效观察

目的：探究更昔洛韦联合干扰素治疗儿童病毒性脑膜炎的临床效果。方法选择我院2012年11月~2013年11月收治86例病毒性脑膜炎患儿，随机分为43例观察组与43例参照组，给予观察组患儿更昔洛韦与干扰素联合治疗，参照组患儿采用利巴韦林治疗，对比两组患儿治疗后的临床疗效。结果经过治疗后，观察组患儿的总有效率(97.67%)比参照组(93.02%)高，两组差异显著(P<0.05)。结论更昔洛韦联合干扰素治疗儿童病毒性脑膜炎的临床效果显著，具有临床大力推广应用意义。     

复方甘草酸苷联合沙利度胺治疗结节性痒疹78例疗效观察

目的 观察复方甘草酸苷联合沙利度胺治疗结节性痒疹的临床疗效.方法 将140例确诊为结节性痒疹的患者分为两组,对照组62例给予复方甘草酸苷片和盐酸西替利嗪片治疗,治疗组78例在对照组治疗基础上加用沙利度胺治疗.比较两组的临床疗效.结果 治疗组痊愈率和总有效率分别为52.6%和96.2%,而对照组分别为22.6%和75.8%,两组比较差异有显著性(P<0.05).结论 复方甘草酸苷联合沙利度胺治疗结节性痒疹疗效满意,值得临床推广.     

胶原蛋白面膜联合口服药物治疗面部 激素依赖性皮炎疗效观察

目的 观察胶原蛋白面膜在面部激素依赖性皮炎治疗中的有效性。方法 选取2015年5月~2018年1月我院200例面部激素依赖性皮炎患者,采用随机数表法分为治疗组103例和对照组97例。治疗组采用胶原蛋白面膜联合口服复方甘草酸苷胶囊、羟氯喹治疗,对照组单纯口服复方甘草胶囊、羟氯喹治疗,观察两组患者治疗有效率及不良反应情况。结果 治疗组治疗有效率为89.32%,高于对照组的72.16%,组间比较,差异有统计学意义（P＜0.01）;治疗后两组患者均未出现明显不良反应,差异无统计学意义（P＞0.05）。结论 胶原蛋白面膜联合复方甘草酸苷胶囊、羟氯喹治疗面部激素赖性皮炎疗效确切,可修复皮肤屏障功能,提高治疗效果,不良反应少,值得临床推广。     

Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster.

This randomized, double-blind, parallel-group study compared the efficacy and safety of famciclovir administered at 250 mg thrice daily with acyclovir 800 mg 5 times daily for the treatment of acute uncomplicated herpes zoster in immunocompetent adults. A total of 55 patients participated in this trial. Twenty seven patients (49.1%) were randomized into the famciclovir plus placebo treatment group and 28 (50.9%) into the acyclovir plus placebo group. Six of the 55 patients did not complete the study. Two of these patients were in the famciclovir plus placebo group and dropped out due to deviation from the study protocol. Four patients in the acyclovir plus placebo group did not complete the study protocol due to adverse events (n = 2), deviation from the protocol (n = 1), or loss to follow-up (n = 1). Treatment was initiated within 72 h of onset of the zoster rash and was continued for 7 days. When treatment was initiated within 72 h, famciclovir was as effective as acyclovir for healing the cutaneous lesion, as indicated by the time to full crusting, loss of acute phase pain, loss of vesicles, and loss of crusts. Famciclovir was well tolerated and had a more favorable adverse event profile compared to acyclovir. Constipation, hematuria, and glycosuria were the most commonly reported adverse events, but only constipation was considered to have a possible relationship to the treatment. In conclusion, famciclovir, administered less frequently and at lower unit doses than acyclovir, is an effective treatment for uncomplicated herpes zoster.     

Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial.

BACKGROUND: Famciclovir, the well absorbed oral pro-drug of penciclovir, is effective in the treatment of herpes zoster when given three times daily. Because the intracellular half-life of penciclovir triphosphate in varicella-zoster virus (VZV)-infected cells (7h) is considerably longer than that of aciclovir triphosphate (1h), it may be possible to administer famciclovir less frequently than three times daily for herpes zoster: aciclovir is administered five times daily. METHODS: 559 immunocompetent adults presenting with herpes zoster whose skin lesions were present for less than 72 h were randomized to receive famciclovir 750 mg once daily (od), 500 mg twice daily (bid), or 250 mg three times daily (tid), or aciclovir 800 mg five times daily. All treatments were given for 7 days. Participants were evaluated until complete healing or for 4 weeks, whichever occurred first. RESULTS: There were no significant differences between the four treatment groups with respect to times to full crusting; loss of vesicles, ulcers and crusts; cessation of new lesion formation; a 50% reduction in the area of affected skin; and the loss of acute pain. CONCLUSIONS: Famciclovir 750 mg once daily, 500 mg twice daily and 250 mg daily, and aciclovir 800 mg five times daily are three times comparable in efficacy with respect to the cutaneous healing of herpes zoster. The current study was not designed to assess the effects of the treatments on postherpetic neuralgia (PHN).     

Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy

Lamivudine therapy improves hepatic necro-inflammatory activity, decreases progression of fibrosis, and suppresses hepatitis B virus (HBV) replication. Famciclovir has also been shown to have some effect in the suppression of HBV replication. The aim of the study was to compare the effect of treatment with lamivudine and famciclovir on serum HBV DNA levels in patients with chronic hepatitis B and to assess safety. A prospective randomised clinical study was carried out on 100 patients with chronic hepatitis B infection (50 patients received lamivudine 100 mg daily and 50 patients received famciclovir 500 mg three times a day for 12 weeks. From the twelfth week onwards, patients were offered lamivudine 100 mg daily up to 48 weeks). Significantly more patients treated by lamivudine than by famciclovir had undetectable HBV DNA levels after 12 weeks of therapy (P < 0.001). The median HBV DNA levels were significantly lower in the lamivudine-treated patients from the second week of treatment onwards (P < 0.001 for all time points up to 12 weeks). At week 16, 4 weeks after the famciclovir treated patients were put on lamivudine, there was no longer any difference in HBV DNA levels between the two groups of patients. Both treatments were well tolerated and no serious adverse events were reported. It was concluded that in Chinese patients with chronic hepatitis B infection, lamivudine achieved effective suppression of HBV DNA levels within 4 weeks of therapy whereas famciclovir had a significantly weaker action.     

Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial

BACKGROUND: Recurrent genital HSV outbreaks are common among those suffering from the disease. Antiviral medications taken as suppressive therapy can reduce the frequency of these recurrences and reduce viral shedding occurring in between recurrences. OBJECTIVES: To investigate the efficacy and safety of oral famciclovir as episodic (125mg twice daily for 5 days) and suppressive (250mg twice daily) treatment of recurrent genital herpes (RGH). STUDY DESIGN: This was a randomized, multicenter, 6-month, open-label study. Efficacy variables were time to first recurrence of RGH symptoms, and change in total score of the Recurrent Genital Herpes Quality of Life (RGHQoL) questionnaire. Subject satisfaction questions were summarized. RESULTS: 384 subjects were randomized. There was a highly statistically significant difference between treatments in time to first recurrence of symptoms in favor of suppressive treatment (p<0.0001). There was no significant difference between treatments in total score of the RGHQoL or in subject satisfaction with treatment. CONCLUSIONS: This study demonstrated that, compared to episodic treatment, suppressive treatment with oral famciclovir may extend the time to symptomatic outbreaks in patients with frequent recurrences of genital herpes.     

拉米夫定与泛昔洛韦联合治疗乙型肝炎病毒慢性感染的临床研究

目的 观察拉米夫定与泛昔洛韦联合治疗乙型肝炎病毒(HBV)慢性感染的临床疗效。方法 慢性乙型肝炎患者90例。设联合治疗组28例，单用拉米夫定组30例，单用泛昔洛韦组32例。联合治疗组给予口服拉米夫定0．1g／d(PO)，泛昔洛韦1．5g／d(PO)，24周。拉米夫定、泛昔洛韦单用组剂量及疗程分别同联合治疗组。结果 3组均无明显副反应，丙氨酸转氨酶(ALT)复常率无差异。3组HBV DNA阴转率分别为89．3％、66．7％、40．6％，差异有显著性。乙型肝炎表面抗原(HBeAg)阴转率分别为28．6％、23．3％、21．9％，差异无显著性。结论 拉米夫定与泛昔洛韦联合用药安全、耐受性好，临床显示联合治疗对HBV DNA的抑制作用显著优于单用药。     

A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection

Patients with frequently recurring genital herpes were enrolled in a double-blind placebo-controlled trial comparing 200-mg acyclovir capsules, given five or two times daily, with placebo. Of 47 placebo recipients, 44 (94 per cent) had recurrences during the 120-day treatment period, compared with 13 (29 per cent) of 45 patients treated with acyclovir five times daily and 18 of 51 (35 per cent) treated with acyclovir twice daily (P less than 0.001 for each regimen compared with placebo). The median time to the first clinical recurrence was 18 days in placebo recipients, compared with over 120 days in both acyclovir-treated groups (P less than 0.001 for both groups compared with placebo). The mean monthly recurrence rate during the medication period was 0.86 in placebo recipients, compared with 0.13 in patients treated with acyclovir five times daily and 0.14 in patients treated with acyclovir twice daily (P less than 0.001 for both groups compared with placebo). While receiving therapy, 86 of 96 acyclovir-treated patients had over a 50 per cent reduction in their pretreatment recurrence rate. Breakthrough recurrences in acyclovir recipients were of shorter duration and associated with a lower frequency of viral shedding than recurrences in placebo recipients. After medication was discontinued, the subsequent recurrence rate returned to pretreatment frequencies. Daily oral acyclovir was well tolerated. We conclude that oral acyclovir given for four months markedly reduces but does not completely prevent recurrences of genital herpes and does not influence the long-term natural history of the disease.     

泛昔洛韦治疗HBV慢性感染的临床研究

目的：观察泛昔洛韦对HBV慢性感染抗病毒的治疗效果。方法：慢性乙型肝炎患者89例，采用随机对照分组，和单用泛昔洛韦治疗组32例，和单用α－干扰素29例和单用拉米夫定28例两个对照组，对比观察三组抗病毒治疗效果。结果：治疗组泛昔洛韦血清HBV DNA阴转率40．62％（13／32），HBeAg阴转率21．88％（7／32）；对照组α－干扰素血清HBV DNA阴转率37．93％（11／29），HBeAg阴转率41．38％（12／29）；拉米夫定血清HBV DNA阴转率67．90％（19／28），HBeAg阴转率21．43％（6／28）。治疗组HBV DNA阴转时间最短1个月，最长3个月，平均1．3个月，无1例出现严重不良反应。结论：泛昔洛韦治疗HBV慢性感染安全有效。     

Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes.

Culture of infectious virus, PCR amplification of viral DNA, and the appearance of genital skin lesions were used as markers to study the course of a recurrence of genital herpes in 40 patients treated with famciclovir or placebo. The highest frequency of patients with skin lesions occurred within the first 36 h following the onset of a recurrence, which also corresponded to the peak in the production of virus. While the timing of the peak in skin lesions was independent of the type of treatment, the frequency of lesions and the release of virus at the lesion site were both reduced by famciclovir treatment. Furthermore, patients receiving this antiviral agent showed a more rapid recovery time and a shorter period during which viral DNA could be detected at the lesion. PCR and then Southern blot hybridization greatly enhanced our ability to detect herpes simplex virus at the lesion site. This procedure proved to be of greater diagnostic value in assessing genital herpes than the standard culture method currently used. In addition, PCR was more sensitive in evaluating treatment effectiveness.     

劳拉西泮结合心理干预治疗广泛性焦虑症的疗效观察

目的探讨劳拉西泮结合心理干预在治疗广泛性焦虑症的疗效。方法将66例符合CCMD-3诊断的广泛性焦虑性神经症患者,随机分为两组,其中对照组33例,单用劳拉西泮治疗;研究组33例,为劳拉西泮结合心理干预联合治疗,两组疗程均为8周,于治疗前、治疗2、4、6、8周末以及半年后随访时分别用焦虑自评量表（SAS）和汉密尔顿焦虑量表（HAMA）评定疗效。结果治疗2周末两组SAS和HAMA评分均较治疗前有非常明显的下降（P〈0.01）;治疗6周末两组间SAS和HAMA评分开始有显著性差异（P〈0.05）;半年后随访,两组间SAS和HAMA评分以及复发率均有非常显著的差异（P〈0.01）。结论劳拉西泮结合心理干预治疗广泛性焦虑症的疗效更好,尤其是远期疗效效果显著,推荐药物与心理联合治疗。